Castle Biosciences
Open
$24.49
Prev. Close
$24.48
High
$24.50
Low
$24.47
Market Snapshot
$707.53M
-29.3
0.66
$332.07M
883
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 883 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.
emptyResult
Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The company is headquartered in Friendswood, Texas and currently employs 883 full-time employees. The company went IPO on 2019-07-25. The firm offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. The company also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). The company also focused on chronic acid reflux related diseases, including esophageal cancer.
Recently from Cashu
Castle Biosciences Advances Melanoma Diagnostics with DecisionDx-Melanoma at AAD Annual Meeting
Castle Biosciences Strengthens Diagnostic Innovations at AAD Annual Meeting Castle Biosciences, Inc. is making significant advancements in the field of dermatology by presenting compelling research fi…
Castle Biosciences Advances Melanoma Management with DecisionDx Test Insights at AAD Meeting
Transforming Melanoma Management: Castle Biosciences Unveils Key Findings at AAD Annual Meeting At the 2026 American Academy of Dermatology (AAD) Annual Meeting, Castle Biosciences, Inc. demonstrates…
Castle Biosciences Reports Revenue Growth Amid Financial Challenges and Ongoing Innovation Efforts
Castle Biosciences Enhances Growth Through Innovation Amid Financial Hurdles Castle Biosciences announces its Q4 earnings results, highlighting a substantial rise in revenue that underscores the compa…
Castle Biosciences Set to Release Anticipated Quarterly Earnings Report on February 26, 2026
Castle Biosciences Prepares for Key Quarterly Earnings Report Castle Biosciences Inc. is positioned to unveil its latest quarterly earnings report on February 26, 2026, amidst heightened anticipation…